Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSX-1004 in Healthy Adults
NCT06005402Phase 1Completed
- Sponsor
- Cessation Therapeutics
- Start
- Aug 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid overdose and opioid use disorder (OUD) comparing CSX-1004 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, serious AEs, and AEs leading to discontinuation at 5 months, Clinical laboratory assessments at 5 months and 4 more. Started Aug 2023; status: completed.
02
Drugs
CSX1004
03
Conditions
opioid overdoseopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06005402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005402.